[Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?]

Autor: P, Beuzeboc, S, Scholl, X S, Garau, A, Vincent-Salomon, P D, Cremoux, J, Couturier, T, Palangié, P, Pouillart
Jazyk: francouzština
Rok vydání: 1999
Předmět:
Zdroj: Bulletin du cancer. 86(6)
ISSN: 0007-4551
Popis: HER2 is overexpressed in about 25% to 30% of breast cancers and associated with poor prognosis, resistance to hormonotherapy and lack of sensitivity to CMF-based adjuvant chemotherapy. Herceptin (trastuzumab), a humanized monoclonal antibody, administered as a single agent, produces objective responses in phase II trials in patients with metastatic breast cancers overexpressing HER2. It has shown a substantial benefit in a phase III trial which compares a standard first line chemotherapy (doxorubicin and cyclophosphamide or taxol alone) to the same chemotherapy with Herceptin in metastatic breast cancer. The Herceptin arm had significantly higher response rate (+ 53%), an improvement in the median duration of response (+ 57%) as well as in time to progression (+ 65%) compared to chemotherapy alone.
Databáze: OpenAIRE